Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel
- 343 Downloads
Bleeding is one of the possible adverse events during clopidogrel therapy. The CYP2C19 gene is the most significant genetic factor which influences response to clopidogrel treatment. We aimed to examine the contribution of the CYP2C19 gene to bleeding occurrence during clopidogrel therapy in Serbian patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
This case–control study included 53 patients who experienced bleeding and 55 patients without bleeding. Bleeding events were defined and classified using the Bleeding Academic Research Consortium (BARC) criteria. All patients were prescribed daily doses of clopidogrel during the 1-year follow-up after PCI. The CYP2C19*17 (c.-806C>T, rs12248560), rs11568732 (c.-889T>G, CYP2C19*20), CYP2C19*2 (c.681G>A; rs4244285) and CYP2C19*3 (c.636G>A; rs4986893) variants were analysed in all 108 patients. Additionally, sequencing of all nine exons, 5′UTR and 3′UTR in the rs11568732 carriers was performed.
Association between bleeding (BARC type ≥ 2) and the CYP2C19*17 variant was not observed [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.2–1.1; p = 0.107). The rs11568732 variant showed significant association with bleeding (OR, 3.7; 95% CI, 1.12–12.44; p = 0.025). Also, we found that the rs11568732 variant appears independently of haplotype CYP2C19*3B, which is contrary to the previous findings.
Our results indicate the absence of CYP2C19*17 influence and turn the attention to the potential significance of the rs11568732 variant in terms of adverse effects of clopidogrel. However, it is necessary to conduct an independent conformation study in order to verify this finding. Also, an analysis of the functional implication of the rs11568732 variant is necessary in order to confirm the significance of this variant, both in relation to its influence on gene expression and in relation to its medical significance.
KeywordsCYP2C19 Clopidogrel PCI Bleeding Pharmacogenetics
The authors deeply appreciate the contributions of all clinical/research staff involved in the present study. This work was supported by grant 173008 from the Ministry of Education, Science and Technological Development, Republic of Serbia.
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest.
- 1.Widimsky P, Wijns W, Fajadet J; European Association for Percutaneous Cardiovascular Interventions et al (2010) Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J 31(8):943–957. https://doi.org/10.1093/eurheartj/ehp492 CrossRefPubMedGoogle Scholar
- 2.Van de Werf F, Bax J, Betriu A; ESC Committee for Practice Guidelines (CPG) et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 29(23):2909–2945. https://doi.org/10.1093/eurheartj/ehn416 CrossRefPubMedGoogle Scholar
- 5.Kazui M, Nishiya Y, Ishizuka T et al (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38(1):92–99. https://doi.org/10.1124/dmd.109.029132 CrossRefPubMedGoogle Scholar
- 6.Gurbel PA, Bliden KP, Hiatt BL et al (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107(23):2908–2913. https://doi.org/10.1161/01.CIR.0000072771.11429.83 CrossRefPubMedGoogle Scholar
- 11.Tsai TT, Ho PM, Xu S et al (2010) Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent). Circ Cardiovasc Interv 3(3):230–235. https://doi.org/10.1161/CIRCINTERVENTIONS.109.919001 CrossRefPubMedGoogle Scholar
- 14.Ingelman-Sundberg M, Daly AK, Nebert DW (eds) The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Available online at: https://www.pharmvar.org/htdocs/archive/index_original.htm
- 16.Niu X, Mao L, Huang Y et al (2015) CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: a systematic review and meta-analysis. J Huazhong Univ Sci Technolog Med Sci 35(2):147–156. https://doi.org/10.1007/s11596-015-1404-7 CrossRefPubMedGoogle Scholar
- 25.Sibbing D, Koch W, Gebhard D et al (2010) Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121(4):512–518. https://doi.org/10.1161/CIRCULATIONAHA.109.885194 CrossRefPubMedGoogle Scholar
- 26.Harmsze AM, van Werkum JW, Hackeng CM et al (2012) The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 22(3):169–175. https://doi.org/10.1097/FPC.0b013e32834ff6e3 CrossRefPubMedGoogle Scholar
- 29.Subraja K, Dkhar SA, Priyadharsini R et al (2013) Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the south Indian Tamilian population. Eur J Clin Pharmacol 69(3):415–422. https://doi.org/10.1007/s00228-012-1381-8 CrossRefPubMedGoogle Scholar
- 34.Mitropoulou C, Fragoulakis V, Rakicevic LB et al (2016) Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. Pharmacogenomics. https://doi.org/10.2217/pgs-2016-0052
- 36.Van de Werf F, Ardissino D, Betriu A; Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology et al (2003) Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 24(1):28–66CrossRefPubMedGoogle Scholar
- 44.Herman D, Dolžan V, Breskvar K (2003) Genetic polymorphism of cytochromes P450 2C9 and 2C19 in Slovenian population. Zdrav Vestn 72:347–351Google Scholar
- 51.Pedersen RS, Brasch-Andersen C, Sim SC et al (2010) Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 66(12):1199–1205. https://doi.org/10.1007/s00228-010-0864-8 CrossRefPubMedGoogle Scholar
- 54.Wei W, Fang L, Wang N et al (2012) Prevalence of CYP2C19 polymorphisms involved in clopidogrel metabolism in Fujian Han population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 29(4):420–425. https://doi.org/10.3760/cma.j.issn.1003-9406.2012.04.009 PubMedGoogle Scholar
- 60.Lewis JP, Horenstein RB, Ryan K et al (2013) The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics 23(1):1–8. https://doi.org/10.1097/FPC.0b013e32835aa8a2 CrossRefPubMedPubMedCentralGoogle Scholar